Methods for treating lymphoma

Abstract

Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided. The methods entail administering to the patient an effective amount of cerdulatinib.

1 - 36 . (canceled) 
     
     
         37 . A method of treating a lymphoma in a human patient in need thereof wherein the patient has one or more mutations in FAT4, CCND3, MYOM2, ZMYM3, NOTCH1, KMT2D, TCF3, ARID1A, AXIN1, SYK, JAK1, JAK3, or TYK2, comprising administering to the patient an effective amount of cerdulatinib or a pharmaceutically acceptable salt, co-crystal, or solvate thereof. 
     
     
         38 . The method of  claim 37 , wherein the patient has one or more mutations in BCL2 or BCL6. 
     
     
         39 . The method of  claim 37 , wherein the lymphoma is relapsed or refractory lymphoma. 
     
     
         40 . The method of  claim 37 , wherein the lymphoma is indolent lymphoma or B cell acute lymphocytic leukemia. 
     
     
         41 . The method of  claim 37 , wherein the patient has one or more mutations in SYK, JAK1, JAK3, or TYK2. 
     
     
         42 . The method of  claim 37 , wherein the effective amount of cerdulatinib is from about 15 mg to about 30 mg, and the step of administering comprises twice daily administration of the about 15 mg to about 30 mg. 
     
     
         43 . The method  claim 37 , wherein the effective amount of cerdulatinib is about 15 mg, about 20 mg, about 25 mg, or about 30 mg, and the step of administering comprises twice daily administration of the about 15 mg, about 20 mg, about 25 mg, or about 30 mg. 
     
     
         44 . The method of  claim 37 , further comprising administering to the patient an effective amount of rituximab. 
     
     
         45 . A method of treating a lymphoma in a human patient in need thereof wherein the patient has one or more mutations in ZMYM3, KMT2D, FAT4, SYK, JAK1, JAK3, or TYK2, comprising administering to the patient an effective amount of cerdulatinib or a pharmaceutically acceptable salt, co-crystal, or solvate thereof. 
     
     
         46 . The method of  claim 45 , wherein the patient has one or more mutations in SYK, JAK1, JAK3, or TYK2. 
     
     
         47 . The method of  claim 45 , wherein the effective amount of cerdulatinib is from about 15 mg to about 30 mg, and the step of administering comprises twice daily administration of the about 15 mg to about 30 mg. 
     
     
         48 . The method  claim 45 , wherein the effective amount of cerdulatinib is about 15 mg, about 20 mg, about 25 mg, or about 30 mg, and the step of administering comprises twice daily administration of the about 15 mg, about 20 mg, about 25 mg, or about 30 mg. 
     
     
         49 . The method of  claim 45 , further comprising administering to the patient an effective amount of rituximab. 
     
     
         50 . A method of treating lymphoma in a human patient in need thereof wherein the patient has one or more mutations in NOTCH1, SETD2, SIGLEC10, SPEN, PCLO, TET2, MK167, FAT3, KRAS, REL, HIST1H1E, KMT2C, KMT2D, or SF3B1, comprising administering to the patient an effective amount of cerdulatinib or a pharmaceutically acceptable salt, co-crystal, or solvate thereof. 
     
     
         51 . The method of  claim 50 , wherein the patient has one or more mutations in SYK, JAK1, JAK2, JAK3, TYK2, TP53, STAT, A20 or ATM. 
     
     
         52 . The method of  claim 51 , wherein the patient has one or more mutations in SYK, JAK1, JAK3, or TYK2. 
     
     
         53 . The method of  claim 50 , further comprising administering to the patient an effective amount of rituximab. 
     
     
         54 . The method of  claim 53 , wherein the administration of the cerdulatinib and the rituximab comprises co-administration of the cerdulatinib and the rituximab. 
     
     
         55 . The method of  claim 50 , wherein the effective amount of cerdulatinib is from about 15 mg to about 30 mg, and the step of administering comprises twice daily administration of the about 15 mg to about 30 mg. 
     
     
         56 . The method  claim 50 , wherein the effective amount of cerdulatinib is about 15 mg, about 20 mg, about 25 mg, or about 30 mg, and the step of administering comprises twice daily administration of the about 15 mg, about 20 mg, about 25 mg, or about 30 mg.